Adempas

Pays: Nouvelle-Zélande

Langue: anglais

Source: Medsafe (Medicines Safety Authority)

Ingrédients actifs:

Riociguat 1mg

Disponible depuis:

Bayer New Zealand Limited

DCI (Dénomination commune internationale):

Riociguat 1 mg

Dosage:

1 mg

forme pharmaceutique:

Film coated tablet

Composition:

Active: Riociguat 1mg Excipient: Crospovidone Hyprolose Hypromellose   Iron oxide yellow Lactose monohydrate Magnesium stearate Microcrystalline cellulose Propylene glycol Purified water Sodium laurilsulfate Titanium dioxide

Type d'ordonnance:

Prescription

Fabriqué par:

Bayer AG

indications thérapeutiques:

Pulmonary arterial hypertension Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, III or IV symptoms.

Descriptif du produit:

Package - Contents - Shelf Life: Blister pack, PP/Al - 42 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, PP/Al - 84 tablets - 36 months from date of manufacture stored at or below 30°C

Date de l'autorisation:

2014-06-25